Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
Sunshine Biopharma (NASDAQ:SBFM) announced the commercial launch of generic doxycycline in Canada on October 20, 2025, with nationwide availability to pharmacies, hospitals and healthcare providers.
The product is supplied as 100 mg tablets, manufactured in compliance with Health Canada regulatory standards and described as therapeutically equivalent to the reference product. Distribution is underway through established pharmacy networks and hospital channels.
Company commentary ties the launch to its anti-infective expansion and cites a broader North American segment inside a global doxycycline market valued at $729 million in 2024 and forecast to reach $1.2 billion by 2030 (CAGR 8.6%).
Sunshine Biopharma (NASDAQ:SBFM) ha annunciato il lancio commerciale della doxycycline generica in Canada il 20 ottobre 2025, con disponibilità a livello nazionale per farmacie, ospedali e fornitori di assistenza sanitaria.
Il prodotto è fornito come compresse da 100 mg, realizzate nel rispetto delle norme regolamentari di Health Canada e descritte come efficaci terapeuticamente rispetto al prodotto di riferimento. La distribuzione è in corso attraverso reti di farmacia consolidate e canali ospedalieri.
I commenti dell'azienda collegano il lancio alla sua espansione anti-infezione e citano un segmento nordamericano più ampio all'interno di un mercato globale della doxycycline valutato a $729 milioni nel 2024 e che si prevede raggiungerà $1.2 miliardi entro il 2030 (CAGR 8.6%).
Sunshine Biopharma (NASDAQ:SBFM) anunció el lanzamiento comercial de doxiciclina genérica en Canadá el 20 de octubre de 2025, con disponibilidad a nivel nacional para farmacias, hospitales y proveedores de atención médica.
El producto se ofrece en tabletas de 100 mg, fabricadas cumpliendo con las normas regulatorias de y descritas como terapéuticamente equivalentes al producto de referencia. La distribución ya está en marcha a través de redes farmacéuticas y canales hospitalarios establecidos.
Los comentarios de la empresa vinculan el lanzamiento a su expansión antiinfecciosa y citan un segmento más amplio de América del Norte dentro de un mercado global de doxiciclina valorado en $729 millones en 2024 y que se prevé alcance $1.2 mil millones para 2030 (CAGR 8.6%).
Sunshine Biopharma (NASDAQ:SBFM)은 2025년 10월 20일 캐나다에서 일반의약품 독시사이클린의 상업적 출시를 발표했고 전국의 약국, 병원 및 보건의료 제공자들에게 공급될 예정입니다.
제품은 100 mg 정으로 제공되며 Health Canada 규제 표준에 따라 제조되었고 기준 제품과 치료적으로 동등하다고 설명됩니다. 기존의 약국 네트워크와 병원 채널을 통해 유통이 진행 중입니다.
회사 코멘터리는 출시를 항감염 확장과 연결하고 2024년 글로벌 독시사이클린 시장에서 7.29억 달러로 평가되었으며 2030년까지 12억 달러에 이를 것으로 전망되는 북미 내 더 넓은 세그먼트를 지목합니다(CAGR 8.6%).
Sunshine Biopharma (NASDAQ:SBFM) a annoncé le lancement commercial de la doxycycline générique au Canada le 20 octobre 2025, avec une disponibilité à l'échelle nationale pour les pharmacies, les hôpitaux et les prestataires de soins de santé.
Le produit est fourni sous forme de comprimés de 100 mg, fabriqués conformément aux normes réglementaires de Santé Canada et décrit comme équivalent thérapeutique au produit de référence. La distribution est en cours via des réseaux de pharmacie établis et des canaux hospitaliers.
Les commentaires de l'entreprise relient ce lancement à son expansion anti-infectieuse et citent un segment nord-américain plus large au sein d'un marché mondial de la doxycycline évalué à 729 millions de dollars en 2024 et qui devrait atteindre 1,2 milliard de dollars d'ici 2030 (TCAC 8,6%).
Sunshine Biopharma (NASDAQ:SBFM) kündigte den kommerziellen Start von generischer Doxycyclin in Kanada am 20. Oktober 2025 an, mit landesweiter Verfügbarkeit für Apotheken, Krankenhäuser und Gesundheitsdienstleister.
Das Produkt wird als 100 mg Tabletten geliefert, hergestellt nach den regulatorischen Standards von Health Canada und als therapeutisch äquivalent zum Referenzprodukt beschrieben. Die Distribution läuft über etablierte Apothekennetze und Krankenhauskanäle.
Unternehmenskommentar verbindet den Start mit seiner Antiinfektiva-Expansion und verweist auf ein breiteres nordamerikanisches Segment innerhalb eines globalen Doxycyclin-Marktes, der 2024 mit 729 Millionen USD bewertet wird und bis 2030 voraussichtlich 1,2 Milliarden USD erreichen wird (CAGR 8,6%).
Sunshine Biopharma (NASDAQ:SBFM) أعلنت عن الإطلاق التجاري للد doxycycline الجنيري في كندا في 20 أكتوبر 2025، مع توفر على المستوى الوطني للصيدليات والمستشفيات ومقدمي الرعاية الصحية.
يُقدم المنتج على شكل أقراص 100 ملغ، مصنّع وفق المعايير التنظيمية لـ Health Canada وموصوف كمكافئ علاجي للمنتج المرجعي. يتم التوزيع عبر شبكات الصيدلة والقنوات الصحية المستشفى.
يربط تعليق الشركة الإطلاق بتوسعها في مضادات العدوى ويشير إلى شريحة أوسع في أمريكا الشمالية ضمن سوق الدوكسي سيلين العالمي الذي قُدِّر بـ 729 مليون دولار في 2024 ومن المتوقع أن يصل إلى 1.2 مليار دولار بحلول 2030 ( CAGR 8.6% ).
Sunshine Biopharma (NASDAQ:SBFM)宣布在加拿大于
产品以100 mg片剂供应，按加拿大卫生部的监管标准生产，并被描述为与参照产品在治疗上等效。分销正在通过既定的药房网络和医院渠道进行。
公司评论将此次推出与其抗感染扩张联系起来，并在全球多西环素市场中指出北美更广泛的细分，2024年全球市场估值为7.29亿美元，预计到2030年将达到12亿美元（CAGR 8.6%）。
- Nationwide distribution to pharmacies, hospitals, and healthcare providers
- Health Canada compliant manufacturing and therapeutic equivalence
- Product format: 100 mg doxycycline tablets available immediately
- Market context: global doxycycline market $729M (2024) to $1.2B (2030), CAGR 8.6%
- No Canada-specific market size or revenue projections disclosed
Insights
Sunshine Biopharma commercially launched generic Doxycycline in Canada, expanding its generic anti-infective footprint.
Sunshine Biopharma’s launch places a widely used, broad‑spectrum antibiotic into Canadian distribution; the product is a 100 mg tablet manufactured under Health Canada‑aligned standards and is being routed through pharmacy and hospital channels. This adds a revenue stream tied to routine, repeat prescription volumes for conditions from acne to Lyme disease and leverages established distribution relationships rather than novel market development.
Outcomes depend on pricing, reimbursement, pharmacy stocking decisions, and market share versus incumbent generics; manufacturing/regulatory compliance reduces technical risk but does not guarantee uptake. The company cites the North American market growth forecast that puts the global Doxycycline market at
Watch: realized Canadian sales volumes, unit pricing versus competitors, and formulary/reimbursement placements over the next 6–12 months from the
FORT LAUDERDALE, FL, QC / ACCESS Newswire / October 20, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company focused on innovative and affordable healthcare solutions, today announced the commercial launch of generic Doxycycline in Canada. This strategic move strengthens the Company's footprint in the Canadian growing antibiotic sector. Doxycycline is now available to pharmacies, hospitals and healthcare providers nationwide.
Doxycycline is a broad-spectrum antibiotic used to treat respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses such as Lyme disease. With high oral bioavailability and a long half-life, Doxycycline continues to be a first-line treatment across multiple antibacterial areas.
The Canadian Doxycycline market is part of a broader North American segment projected to grow steadily through 2030. While exact Canadian figures are segmented within regional data, the North American Doxycycline market is expected to contribute significantly to the global market, which was valued at approximately
"Launching Doxycycline in Canada aligns with our mission to deliver high-quality, affordable medications that meet real clinical needs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "We are proud to support healthcare providers with a trusted antibiotic backed by rigorous manufacturing and regulatory standards."
Sunshine Biopharma's doxycycline comes in 100 mg tablets and is manufactured in compliance with Health Canada's regulatory framework, ensuring therapeutic equivalence to the reference product. Distribution is underway through established pharmacy networks and hospital channels.
This launch follows Sunshine Biopharma's recent expansion into anti-infective therapies and complements the Company's growing pipeline of generic drugs targeting infectious diseases, oncology, and metabolic disorders.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 76 generic prescription drugs on the market in Canada and more than 12 additional drugs scheduled to be launched in 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What did Sunshine Biopharma (SBFM) announce on October 20, 2025 about doxycycline in Canada?
What form and strength is Sunshine Biopharma's doxycycline (SBFM) sold in Canada?
Is Sunshine Biopharma's doxycycline approved by Health Canada (SBFM)?
How large is the doxycycline market cited in Sunshine Biopharma's (SBFM) announcement?
Will Sunshine Biopharma's doxycycline be available to hospitals immediately (SBFM)?
